| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.064 | 0.4 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.4 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.078 | 0.4 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |